| First Year N (%) | Second Year N (%) | Third Year N (%) | p-trenda |
---|---|---|---|---|
All children | N = 66 | n = 159 | n = 352 | Â |
Age (yrs): Median (IQR) | 3.1 (1.0, 8.1) | 1.7 (0.6, 5.2) | 0.4 (0.0, 1.9) | <0.0001 |
   <1 | 17 (25.8) | 57 (35.9) | 224 (63.6) | <0.0001 |
   1-1.9 | 9 (13.6) | 31 (19.5) | 46 (13.1) |  |
   2-4.9 | 17 (25.8) | 26 (16.4) | 38 (10.8) |  |
   5-9.9 | 14 (21.2) | 29 (18.2) | 31 (8.8) |  |
   ≥ 10 | 9 (13.6) | 16 (10.1) | 13 (3.7) |  |
Male sex | 34 (51.5) | 68 (42.8) | 182 (51.7) | 0.38 |
Distance travelled (km): | Â | Â | Â | 0.008 |
   Median (IQR) | 22 (9, 40) | 30 (13, 48) | 35 (20, 50) |  |
   Missing | 11 (16.7) | 41 (25.8) | 80 (22.7) |  |
HIV-infected children | N = 48 | N = 99 | n = 124 | Â |
Age (yrs): Median (IQR) | 4.9 (2.6, 9.3) | 3.9 (1.9, 7.5) | 2.8 (1.7, 6.5) | 0.003 |
Male sex | 24 (50.0) | 41 (41.4) | 66 (53.2) | 0.39 |
Self-reported history of tuberculosis | 13 (27.1) | 11 (11.1) | 15 (12.1) | 0.04 |
WAZ: Median (IQR) | -3.0 (-3.8, -2.3) | -2.3 (-4.1, -1.5) | -3.0 (-3.9, -1.5) | Â |
   Underweight | 27 (81.8) | 43 (57.3) | 69 (70.4) | 0.71 |
   Missing | 15 (31.3) | 24 (24.2) | 26 (21.0) |  |
WHO stage | Â | Â | Â | Â |
   1 | 4 (10.8) | 9 (11.5) | 16 (18.8) | 0.04 |
   2 | 10 (27.0) | 32 (41.0) | 34 (40.0) |  |
   3 or 4 | 23 (62.2) | 37 (47.4) | 35 (41.2) |  |
   Missing | 11 (22.9) | 21 (21.2) | 39 (31.5) |  |
CD4%: Median (IQR) | 19.0 (9.0, 25.0) | 13.0 (9.5, 19.4) | 20.2 (13.7, 27.6) | 0.01 |
   Missing | 41 (85.4) | 50 (50.5) | 45 (36.3) |  |
   Severe immunodeficiencyb | 3 (25.0) | 36 (60.0) | 36 (41.9) | 0.59 |
CD4 count (cells/mm3): | Â | Â | Â | Â |
   Median (IQR) | 453 (257, 663) | 513 (264, 786) | 693 (338, 998) | 0.01 |
   Missing | 36 (75%) | 39 (39.4) | 38 (30.6) |  |
Eligible for ARTc | 22 (55.0) | 58 (61.7) | 61 (54.5) | 0.69 |
   Missing | 8 (16.7) | 5 (5.1) | 12 (9.7) |  |